1-20 of 52
A Prat
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract TF2-3: Molecular heterogeneity in HER2+ breast cancer - can outcomes be predicted?

A Prat
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): TF2-3.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-TF2-3
Published: 15 February 2022
View article
Journal Articles

Abstract SP121: Personalized treatment for early stage HER2-positive breast cancer

A Prat
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): SP121.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-SP121
Published: 15 February 2021
View article
Journal Articles

Abstract PD9-04: FGFR4 as a key regulator of HER2E subtype in the primary and metastatic setting

S Garcia Recio, JS Parker, C Fan, K Mott, X He, JM Cejalvo, F Brasó Maristany, P Galván, A Lluch, J Albanell, F Rojo, E Martinez de Dueñas, A Prat, CM Perou
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): PD9-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-PD9-04
Published: 15 February 2019
View article
Journal Articles

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

O Metzger, S Mandrekar, S Loibl, C Mundhenke, S Seiler, P Valagussa, E Lim, D Tripathy, EP Winer, C Huang, L Carey, P Francis, K Miller, MP Goetz, A Prat, S Loi, I Krop, L Gianni, S Delalogue, I Vaz-Luis, T Dockter, J Lanzillotti, E Ciruelos, AM DeMichele
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): OT3-02-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-OT3-02-07
Published: 15 February 2019
View article
Journal Articles

Abstract OT3-02-05: CORALLEEN: A phase 2 clinical trial of chemotherapy or letrozole plus ribociclib as neoadjuvant treatment for postmenopausal patients with luminal B/HER2-negative breast cancer

J Gavila, C Saura, M Oliveira, E Ciruelos, X Gonzalez, L de la Peña, B Bermejo de las Heras, M Muñoz, P Fernandez, P Villagrasa, V Ortega, R Lopez, P Celiz, T Pascual, A Prat
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): OT3-02-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-OT3-02-05
Published: 15 February 2019
View article
Journal Articles

Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial

M Lambertini, C Campbell, RD Gelber, G Viale, A McCullough, L Tonghua, F Hilbers, LA Korde, O Werner, S Chumsri, C Jackisch, AC Wolff, I Vaz-Luis, AR Ferreira, A Prat, A Moreno Aspitia, M Piccart, S Loi, E de Azambuja
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P2-08-14.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P2-08-14
Published: 15 February 2019
View article
Journal Articles

Abstract P2-08-17: Tumor inflammation signature (TIS), intrinsic subtypes and chemo-endocrine score (CES) in metastatic triple-negative breast cancer (mTNBC): A SOLTI biomarker program study

T Pascual, C Pernaut, P Tolosa, P Galvan, C Bárcena, M Vidal, L Manso, B Adamo, M Dueñas, M Muñoz, N Chic, B Gonzalez-Farre, P Villagrasa, E Ciruelos, A Prat
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P2-08-17.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P2-08-17
Published: 15 February 2019
View article
Journal Articles

Abstract P2-08-06: Standardized nCounter-based determination of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor status in breast cancer

T Pascual, YS Tsai, M Martín, A Lluch, J Cortes, A Llombart, P Conte, V Guarneri, MF Rimawi, E Alba, M Ruiz-Borrego, F Rojo, J de la Haba, R Schiff, B Adamo, M Vidal, L Paré, N Chic, M Muñoz, P Galvan, B Gonzalez-Farre, HA Brauer, A Sullivan, P Nuciforo, JS Parker, A Prat
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P2-08-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P2-08-06
Published: 15 February 2019
View article
Journal Articles

Abstract P3-10-03: Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab

T Díaz-Redondo, R Lavado-Valenzuela, N Ribelles, T Pascual, F Galvez, A Falcón, MC Alamo, C Morales, M Amerigo, A Prat, E Alba
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P3-10-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P3-10-03
Published: 15 February 2019
View article
Journal Articles

Abstract P5-11-04: Anti-proliferative effect of oral metronomic vinorelbine (mVNB) in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): A randomized, three-arm, window-of-opportunity study

A Prat, B Adamo, T Pascual, JA Perez Fidalgo, S Blanch, N Martínez, P Gomez Pardo, A Lopez Gonzalez, L Murillo Jaso, K Amillano, M Vidal, L Paré, J Canes, P Galvan, B Gonzalez Farre, V Ortega Cebrián, X Gonzalez, M Bellet Ezquerra, P Villagrasa, E Ciruelos
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P5-11-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P5-11-04
Published: 15 February 2019
View article
Journal Articles

Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer

E Ciruelos, P Villagrasa, L Paré, M Oliveira, S Pernas, J Cortés, J Soberino, B Adamo, S Vazquez, N Martínez, A Perelló, B Bermejo, E Martínez, I Garau, M Melé, S Morales, P Galván, T Pascual, J Canes, P Nuciforo, X Gonzalez, A Prat
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): PD3-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-PD3-03
Published: 15 February 2019
View article
Journal Articles

Abstract P6-18-02: Primary and secondary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

S Pernas, P Villagrasa, PG Nuciforo, A Vivancos, M Scaltriti, J Rodón, O Burgués, J Canes, M Dueñas, F Cecchi, M Vidal, A Lluch, A Perelló, A Llombart, J Dorca, A Montaño, M Oliveira, G Ribas, I Rapado, L Paré, A Prat, E Ciruelos
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-18-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-18-02
Published: 15 February 2019
View article
Journal Articles

Abstract P6-17-08: Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy

G Griguolo, E Holgado, J Cortés, R Fasani, T Pascual, L Paré, B Bermejo, M Oliveira, S Morales, N Martinez, M Vidal, S Pernas, R Lopez, M Muñoz, P Galvan, I Garau, L Manso, J Alarcón, E Martínez, P Villagrasa, A LLombart-Cussac, A Prat, P Nuciforo
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-17-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-17-08
Published: 15 February 2019
View article
Journal Articles

Abstract P6-17-05: Independent validation of a combined biomarker based on the PAM50 HER2-enriched subtype and ERBB2 mRNA levels following HER2 blockade without chemotherapy in the PerELISA phase II trial

A Prat, G Griguolo, MV Dieci, G Bisagni, A Frassoldati, GV Bianchi, T Pascual, L Pare, P Galvan, L Urso, P Conte, V Guarneri
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-17-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-17-05
Published: 15 February 2019
View article
Journal Articles

Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results

J Crown, M-P Sablin, J Cortés, J Bergh, S-A Im, Y-S Lu, N Martínez, P Neven, KS Lee, S Morales, JA Pérez-Fidalgo, D Adamson, A Goncalves, A Prat, G Jerusalem, L Schlieker, R-M Espadero, T Bogenrieder, D Chin-Lun Huang, P Schmid
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-21-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-21-01
Published: 15 February 2019
View article
Journal Articles

Abstract P6-18-17: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population

J Salvador, EM Ciruelos, A Prat, B Jiménez-Rodríguez, L de la Cruz, N Martínez, R Villanueva Vázquez, R de Toro, A Antón, F Moreno, I Alvarez, J Gavila, V Quiroga, E Vicente, J de la Haba, S González-Santiago, N Díaz, A Barnadas, B Cantos Sánchez de Ibargüen, JI Delgado, M Bellet, A Gimeno, S Sanz, M Martin
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-18-17.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-18-17
Published: 15 February 2019
View article
Journal Articles

Abstract P6-17-07: Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer

F Brasó-Maristany, G Griguolo, A Llombart-Cussac, T Pascual, L Paré, B Bermejo, M Oliveira, S Morales, N Martinez, M Vidal, S Pernas, R Lopez, M Muñoz, P Galvan, I Garau, L Manso, J Alarcón, E Martínez, P Villagrasa, J Cortés, A Prat
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P6-17-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P6-17-07
Published: 15 February 2019
View article
Journal Articles

Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

O Gluz, U Nitz, C Liedtke, A Prat, M Christgen, F Feuerhake, M Garke, E-M Grischke, H Forstbauer, M Braun, M Warm, J Hackmann, C Uleer, B Aktas, C Schumacher, S Kuemmel, E Pelz, D Gebauer, L Paré, R Kates, R Wuerstlein, HH Kreipe, N Harbeck
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): GS5-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-GS5-06
Published: 15 February 2019
View article
Journal Articles

Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC)

A Prat, D Slamon, SA Hurvitz, MF Press, G Lewis Phillips, V Lopez Valverde, A Kiermaier, H-J Helms, M Martin, SL de Haas
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): PD3-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-PD3-06
Published: 15 February 2018
View article
Journal Articles

Abstract OT3-06-02: A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy)

D Yee, MP Sablin, H Iwata, EL Johnston, T Bogenrieder, J Serra, H Hua, P Lo Russo, A Prat
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): OT3-06-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-OT3-06-02
Published: 15 February 2018
View article